Drugs / VRDN-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06384547 | May 2024 → May 2025 | endocrine exophthalmos | Viridian Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRDN-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06384547 ↗ |
| Action | Inhibit | “a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R)” NCT06384547 ↗ |
| Modality | Monoclonal antibody | “VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor” NCT06384547 ↗ |